Practical management of adverse events associated with cabozantinib treatment in patients with renal-cell carcinoma.

about

Cabozantinib for the Management of Metastatic Clear Cell Renal Cell Carcinoma

P2860

Q57481747-8A5465EC-8D05-4218-9C54-D2591AFC86CC

P2860

Practical management of adverse events associated with cabozantinib treatment in patients with renal-cell carcinoma.

Item

http://www.wikidata.org/entity/Q45329617

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Practical management of advers ...... nts with renal-cell carcinoma.

@en

Practical management of advers ...... nts with renal-cell carcinoma.

@nl

type

Item

label

Practical management of advers ...... nts with renal-cell carcinoma.

@en

Practical management of advers ...... nts with renal-cell carcinoma.

@nl

prefLabel

Practical management of advers ...... nts with renal-cell carcinoma.

@en

Practical management of advers ...... nts with renal-cell carcinoma.

@nl

P1476

Practical management of advers ...... nts with renal-cell carcinoma.

@en

P2093

Benjamin S Gerendash

http://www.w3.org/2001/XMLSchema#string

Patricia A Creel

http://www.w3.org/2001/XMLSchema#string

P2860

Drug therapy for the management of cancer-related fatigue

The treatment landscape in thyroid cancer: a focus on cabozantinib

Overview and management of cardiac adverse events associated with tyrosine kinase inhibitors

Management of dose variability and side effects for individualized cancer pharmacotherapy with tyrosine kinase inhibitors

2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)

Putting evidence into practice: an update of evidence-based interventions for cancer-related fatigue during and following treatment.

Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A Gynecologic Oncology Group Study.

Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy

Aerodigestive fistula formation as a rare side effect of antiangiogenic tyrosine kinase inhibitor therapy for thyroid cancer

Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors.

P304

5053-5064

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/OTT.S145295

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-10-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29089775

http://www.w3.org/2001/XMLSchema#string

P932

5656352

http://www.w3.org/2001/XMLSchema#string

Practical management of adverse events associated with cabozantinib treatment in patients with renal-cell carcinoma.

about

P2860

P2860

Practical management of adverse events associated with cabozantinib treatment in patients with renal-cell carcinoma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P577

P698

P932